Free Trial

SAB Biotherapeutics (SABS) Earnings Date, Estimates & Call Transcripts

SAB Biotherapeutics logo
$2.10 -0.02 (-0.94%)
Closing price 08/28/2025 03:59 PM Eastern
Extended Trading
$2.08 -0.02 (-0.71%)
As of 08:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SAB Biotherapeutics Earnings Summary

SAB Biotherapeutics issued Q2 2025 earnings on August 7, 2025, reporting an EPS of -$1.09, which missed analysts' consensus estimates of -$0.82 by $0.27. With a trailing EPS of -$4.00, SAB Biotherapeutics' earnings are expected to grow next year, from ($3.69) to ($2.98) per share.

Upcoming Q3
Earnings Date
Nov. 5Before Market OpensEstimated
Consensus EPS
(Aug. 7)
-$0.82
Actual EPS
(Aug. 7)
-$1.09 Missed By -$0.27

Q2 2025 Earnings Resources

SABS Upcoming Earnings

SAB Biotherapeutics' next earnings date is estimated for Wednesday, November 5, 2025, based on past reporting schedules.

Get SAB Biotherapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SAB Biotherapeutics and other key companies, straight to your inbox.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

SABS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

SABS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

SAB Biotherapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20251-$1.14-$1.14-$1.14
Q2 20252-$1.10-$0.58-$0.84
Q3 20252-$1.04-$0.07-$0.56
Q4 20252-$1.18-$0.06-$0.62

SAB Biotherapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
11/5/2025
(Estimated)
--------
8/7/2025Q2 2025-$0.82-$1.09 -$0.27-$1.09$0.10M-
5/9/2025Q1 2025-$1.00-$0.56+$0.44-$0.56$0.13M-
3/28/2025Q4 2024-$1.16-$1.23 -$0.07-$1.23$0.12M$0.05M
11/6/2024--$1.07-$1.12 -$0.05-$1.12$0.50M-
8/8/2024--$1.13-$0.79+$0.34-$0.79-$0.26M
5/20/2024Q1 2024-$0.98-$0.54+$0.44-$0.54-$0.95M
11/13/2023Q3 2023-$0.10-$0.10--$0.10-$1.27M

SAB Biotherapeutics Earnings - Frequently Asked Questions

SAB Biotherapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 5th, 2025 based off last year's report dates. Learn more on SABS's earnings history.

In the previous quarter, SAB Biotherapeutics (NASDAQ:SABS) missed the analysts' consensus estimate of ($0.82) by $0.27 with a reported earnings per share (EPS) of ($1.09). Learn more on analysts' earnings estimate vs. SABS's actual earnings.

SAB Biotherapeutics (NASDAQ:SABS) has a recorded annual revenue of $1.32 million.

SAB Biotherapeutics (NASDAQ:SABS) has a recorded net income of -$34.10 million. SABS has generated -$4.00 earnings per share over the last four quarters.

SAB Biotherapeutics' earnings are expected to grow from ($3.69) per share to ($2.98) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:SABS) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners